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Triple negative breast cancers (TNBC) comprise a highly aggressive cancer 
subtype with high mortality rates, high frequency of metastatic disease and a 
lack of targeted therapies. A fraction of these cancers also demonstrate 
amplification of the NTRK1 gene. The protein product of the NTRK1 gene, TrkA, 
is a receptor tyrosine kinase (RTK) that recognizes neuronal growth factor (NGF) 
leading to downstream signaling through MAPK and other pathways that 
promote survival and proliferation. Pan-Trk inhibitors have been developed 
against rare cancers with NTRK translocations that result in constitutive Trk 
kinase activity. Expansion of these inhibitors’ application to amplifications, 
particularly in TNBC, offers the potential for targeted therapies. Here, we 
engineered non-tumorigenic immortalized human mammary epithelial cell lines 
and human breast cancer cell lines to overexpress TrkA. Overexpressing clones 
demonstrated cancerous and pro-metastatic phenotypes, which were reversed 
upon exposure to the Trk inhibitor larotrectinib. In vitro, the MCF10A and 
hTERT-IMEC engineered cell lines showed growth factor independence, 
increased downstream proliferative and pro-survival signaling, alterations in 
three-dimensional culture, and migratory phenotypes in increased wound 
healing and microchannel migration. In vivo, TrkA-overexpressing MCF7 cells 
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showed increased tumor growth and acquired the capacity to establish 
disseminated disease. Our results demonstrate the potential clinical utility of 
larotrectinib for targeting NTRK1 amplified breast cancers and inhibiting 
metastasis. 
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Breast cancer background 
 
Breast cancer represents one of the leading causes of cancer mortality 
among women globally, with 1.2 million cases worldwide and 540,000 new 
diagnoses annually, causing 500,000 deaths (1). Triple negative breast cancers 
(TNBC), which do not express ER (estrogen receptor-alpha), PR (progesterone 
receptor), or targetable levels of HER2 (human epidermal growth factor 2) 
represent a particular challenge as a highly aggressive form of breast cancer with 
high rates of recurrence, metastasis and mortality (2). TNBC generally have poor 
outcomes and an aggressive disease course with options for therapy limited to 
surgical intervention, radiation and cytotoxic chemotherapies. Unlike breast 
cancers expressing ER/PR and/or overexpressing HER2, these cancers are 
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generally not candidates for treatment with targeted therapies such as 
trastuzumab and hormonal therapies (2-4). In spite of robust response to first line 
surgical and chemotherapeutic treatment, TNBC frequently recur and 
metastasize. After the establishment of treatment-resistant tumor populations, 
patients are left with few options, and no targeted therapies are currently 
available. TNBC is particularly common in patients with germline mutations in 
the BRCA1 gene, and TNBC also have a high rate of somatic TP53 mutations (5, 
6).  
Cancer formation is generally understood to result from the accumulation 
of somatic mutations which in combination produce a proliferative, replicatively 
immortal, cell death resistant tumor cell population which can evade growth 
suppression and the immune system, promote angiogenesis, and invade and 
metastasize. The genomic instability underlying the progression to these 
characteristics also results in a multitude of mutations in many cancer cells. 
Tumors accumulate mutations which independently promote tumorigenesis, 
termed driver mutations, and those which do not, termed passenger mutations 
(7). Driver mutations are further divided into oncogenes, which provide a 
growth advantage by their amplification or overexpression, and tumor 
suppressors, which promote tumorigenesis by their absence through suppression 
or loss of function mutation. Although driver mutations represent the most 
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promising targets for the development of targeted therapies, passenger 
mutations may equally find research utility as targets or detectable markers of 
tumor burden (7). TrkA amplification, the subject of this research, is a putative 
driver mutation in cancer (1).  
TrkA background and function 
TrkA translocations  
TrkA was first identified in the cancer context as the unknown protein 
kinase component of an oncogenic fusion protein in two colon cancer patients in 
1982 (1). This translocation, producing transformation in NIH-3T3 cells, was later 
identified by cloning and sequencing as a fusion between tropomyosin and 
TrkA.  Oncogenic gene fusions incorporating the 3' tyrosine kinase region of 
TrkA remain the best characterized TrkA alterations in cancer, arising at a low to 
moderate level among a range of cancer types and resulting in ligand-
independent, constitutively activated proliferation and survival pathways. 
Oncogenic rearrangements of NTRK1 have been identified by targeted next 
generation sequencing (NGS) in a number of cancers, resulting in constitutive 
activation and downstream signaling (1, 8). The incidence of such translocations 
motivated the development of pan-Trk inhibitors, such as larotrectinib. Pan-Trk 
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inhibitors have shown promising early results in clinical trials (9, 10) as targeted 
therapies.  
TrkA Amplifications 
TrkA amplifications or copy number increase arise in a variety of cancers, 
reported at rates up to 22% in breast cancers according to cBioPortal (Figure 2, 
Table 3). Although a relatively small percentage, this represents tens of 
thousands of newly diagnosed patients each year in the United States alone. In 
TCGA data from 2015, TrkA alterations comprised primarily of amplifications 
correlated to a 40 month survival disadvantage (Figure 3). In addition, research 
has demonstrated that genetic alterations in a small percentage of cancers can 
lead to dramatically improved outcomes with appropriate targeted therapies, for 
example, EGFR mutations in non-small cell lung cancers (11). When interrogated 
specifically for breast cancers lacking HER2, ER, and PR expression (TNBC), 
rates of TrkA amplification were as high as 22% in some studies (Table 3). The 
mechanism of these pan-Trk inhibitors targets the kinase function of the Trk 
molecules by blocking the ATP binding site, and would therefore be expected to 





TrkA gene and protein structure 
Tropomyosin receptor kinase A (TrkA), encoded by NTRK1 is the 
membrane-bound receptor tyrosine kinase (RTK) that serves as a high affinity 
receptor for the neuronal growth factor (NGF) (12). NTRK1 is located on 
chromosome 1q23.1 and contains 16 exons, all coding. The predominant 
transcript variant encodes a 2492 base pair mRNA which is translated to an 87.5 
kDa membrane-bound high affinity receptor comprised of 796 amino acids. TrkA 
is a member of the tropomyosin kinase receptor family, which also includes TrkB 
and TrkC, encoded by NTRK2 and NTRK3 respectively. Trk family receptors are 
comprised of an extracellular domain, a single transmembrane domain, and an 
intracellular domain. The high level of homology within this family is reflected 
in the extracellular domain of each member, which contains two cysteine clusters 
bracketing three leucine-rich motifs, and two immunoglobin-like C2 regions. The 
ATP binding site, which is the target for larotrectinib, is located within the 
intracellular domain. These receptors exist in a dynamic equilibrium between the 
lower ligand affinity monomeric form and the higher affinity dimeric form. 
Binding of the ligand (in the case of TrkA, dimeric NGF) stabilizes the dimeric 




TrkA mediated signaling 
 Following binding of the ligand and dimerization, autophosphorylation 
of tyrosine residues Y490 and Y785 of TrkA permits binding of adaptor 
molecules including Shc and PLC-g, resulting in downstream catalytic activation 
of the Ras/MAP Kinase and PI3K pathways, promoting proliferation and 
survival (13). The normal physiologic function for this pathway is in the 
development of neuronal tissues during organogenesis, promoting survival, 
differentiation and proliferation of neurons in the central and peripheral nervous 
systems. However, when inappropriately or constitutively activated, these 
signaling cascades promote growth and survival in tumors. A putative autocrine 
loop for this signaling pathway has been identified in breast cancer (14).   
Early positive results from clinical trials  
Targeted therapeutics inhibiting the NTRK translocations have been 
developed with promising results recently reported (1, 8, 15, 16), and clinical 
trials have shown early positive results (10). The potential to expand these 
targeted medications to other, difficult to treat cancers offers possibilities for 













The non-tumorigenic human breast epithelial cell line MCF10A and its 
derivatives were cultured in DMEM/F12 (1:1) supplemented with 1% Penicillin-
Streptomycin (Life Technologies, Carlsbad, CA), 0.1 ng/uL cholera toxin (Sigma-
Aldrich, St Louis, MO), 10ug/mL insulin (Life Technologies), 20 ng/mL EGF 
(Sigma-Aldrich), 0.5 ug/mL hydrocortisone (Sigma-Aldrich) and 5% horse serum 
(Life Technologies). The non-tumorigenic, human TERT-immortalized human 
breast epithelial cell line hTERT-IMEC and its derivatives were cultured in 
DMEM/F12 supplemented with 1% Pen/Strep, 10% charcoal-dextran stripped 
8 
 
fetal bovine serum (FBS) (Life Technologies), cholera toxin, insulin, 
hydrocortisone and EGF, with recovery for 24 hours in MCF10A media after 
trypsinization for plating or passaging. The human breast cancer cell line MCF7 
and its derivatives were cultured in DMEM supplemented with 1% Pen/Strep 
and 5% FBS. NTRK1-overexpressing clones and CD74-NTRK1 fusion expression 
clones were continuously cultured under Geneticin (Life Technologies) selection, 
beginning 24 hours after transfection. MCF10A parental, hTERT-IMEC parental, 
and MCF7 parental were purchased from ATCC.  
hTERT-IMEC-derived cell lines were prepared for growth factor-reduced 
assays by a 48-hour arrest in DMEM/F12 with 5% charcoal/dextran stripped FBS 
(C/D FBS), 1% Pen/Strep, hydrocortisone, and cholera toxin after being 
trypsinized, spun down and washed twice with HBSS. MCF7-derived cell lines 
for low growth factor experiments were prepared for plating by a 48-hour arrest 
in DMEM with 5% C/D FBS, 1% Pen/Strep, after being trypsinized, spun down 
and washed twice with HBSS. MCF10A-derived cell lines were prepared for 
plating for low growth factor conditions (physiologic EGF and no EGF) by 
trypsin and two HBSS washes and spins (17).  
Parental cell lines were authenticated by short tandem repeat profiling 
analysis at the Johns Hopkins Genetic Resources Core Facility. A complete list of 
cell lines generated and used in this study can be found in Table 1.  
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Overexpression of NTRK1 or CD74-NTRK1 cDNA in human cells: 
NTRK1 cDNA was purchased as pCMV6-AC-GFP-NTRK1 (RC213091, 
Origene, Rockville, MD) and subcloned into the pIRESneo3 vector (Clontech, 
Mountain View, CA) by amplification (Table 2) and addition of cut sites before 
digestion and ligation into pIRESneo3.  Cells were transfected with pIRESneo3-
NTRK1 using the Fugene 6 system (Promega, Fitchburg, WI). 24 hours after 
transfection, cells were trypsinized and changed to selection media containing 
Geneticin (Life Technologies) and allowed to grow until colonies were visually 
identified, at which point single cell selection was performed and multiple single 
clones were isolated. This procedure was repeated in each cell line with the 
pIRESneo3 empty vector as a control (17). CD74-NTRK1 fusion cDNA was 
generously provided by Pasi A Janne (8). Transfection and selection were 
performed as above.  
Immunoblotting:  
Cells were washed twice with HBSS (Life Technologies) and plated at 
500,000 cells per well in 6-well plates. After 24 hours, media was changed to 
specified conditions. 24 hours after media change, cells were harvested for 
protein lysates and immunoblotting was performed as previously described (17). 
Briefly, cells were washed twice with HBSS and collected in Laemlli buffer 
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(Invitrogen, Carlsbad, CA) with 10% beta mercaptoethanol, placed at 100C for 10 
minutes and frozen. Protein was quantified with Pierce 660nM Reagent 
(Invitrogen) and lysates loaded accordingly into NuPage 4-12% gel (Invitrogen) 
and run at 200V for 35 minutes. Gels were transferred to polyvinylidine 
difluoride (PVDF) 45uM membranes (Invitrogen) for 1 hour at 30V. Membranes 
were blocked with 10% milk in TBST for 1 hour, placed in primary antibody in 
5% milk at 4C overnight, washed 4x5 minutes in TBST, placed in horseradish 
peroxidase-conjugated secondary antibody in 5% at room temperature for 1 
hour, washed 20 minutes with TBST, 2x5 minutes in TBST, 5 minutes in TBS, and 
finally placed in ECL reagent solution for 1 minute before exposure of X-ray film 
for visualization.  
The primary antibodies used in this study include anti-TrkA rabbit 
antibody (2505; Cell Signaling Technology, Danvers, MA), anti-pTrkA rabbit 
antibody (9141S; Cell Signaling), anti-hSerpin E1/PAI-1 mouse antibody (MAB 
1786; R&D Systems, Minneapolis, MN), anti-phospho-AKT rabbit antibody 
(9271; Cell Signaling), anti-AKT rabbit antibody (9272; Cell Signaling), anti-
phospho-p44/p42 MAP kinase rabbit antibody (4370; Cell Signaling), anti-
p44/p42 MAP kinase rabbit antibody (9102; Cell Signaling), anti-phospho-
P90RSK rabbit antibody (9341; Cell Signaling), anti-P90RSK rabbit antibody 
(9333; Cell Signaling), anti-phospho-p70 S6 kinase rabbit antibody (9205; Cell 
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Signaling), anti-p70 S6 kinase rabbit antibody (9202; Cell Signaling), and anti-
GAPDH rabbit antibody (5174; Cell Signaling) (17, 18).  
Cell proliferation assays:  
Cell counting: 
Exponentially growing cells were washed twice in HBSS before plating at 
30,000 cells/well in 12-well plates in triplicate. After 24 hours, media was 
changed to specified conditions. Cells were trypsinized and counted using a 
Beckman-Coulter cell counter at days 2, 4, and 6 after plating (17). Assay media, 
DMEM/F12 supplemented with 1% penicillin-streptomycin, 10% charcoal-
dextran stripped fetal bovine serum (Life Technologies), 0.1 ng/uL cholera toxin, 
0.5 ug/mL hydrocortisone, 10ug/mL insulin for MCF10A. Epidermal growth 
factor (EGF) added at 0.2 ng/mL. NGF, neuronal growth factor, 100ng/mL for 
MCF10A-derived cells, 12.5ng/mL for hTERT-IMEC derived cells. 
Crystal violet:  
Cells were plated at 30,000 cells/well in 24-well or 48-well plates. As 
appropriate, media was replaced with media containing drug at 24 hours after 
plating.  At 1 week, cells were washed twice with HBSS before addition of a .05% 
crystal violet solution in 70% ethanol for 15 minutes, rinsed, allowed to dry, and 
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imaged (17). Images were taken from larger plates in smaller groups to avoid 
parallax effect. 
Colony formation in semisolid media: 
 A solution of cells at 30,000 cells/mL media was prepared and mixed 1:1 
with a 1x media, 1.2% UltraPure Agarose (Life Technologies) solution before 
plating on top of a layer of 0.6% agarose solution. After solidifying, media was 
added on top and replaced weekly over a course of 2-4 weeks before staining 
with .05% crystal violet in 70% ethanol and imaging. Colonies were counted in 
each field of view in each of four 10x images per well per replicate. Photographs 
were taken with a Nikon SMZ 1500 stereoscopic zoom microscope (17).  
Acinar morphogenesis assay: 
Acinar morphogenesis assays were performed with growth factor reduced 
Matrigel (BD Biosciences, San Jose, CA) as previously described (17). Briefly, a 
solution of 4% Matrigel in media with 30,000 cells/well was plated in 8-well 
chamber slides on top of a layer of 4% Matrigel in media. Media with Matrigel in 
appropriate conditions was added weekly over a course of 1-4 weeks and images 
taken at appropriate time points at 40x with a Nikon SMZ 1500 stereoscopic 
zoom microscope (17).  
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Wound healing assay: 
Cells were plated at 2 million cells/well in 6-well plates and checked for 
confluence the following day. Scratch wounds were made in a cross pattern 
using a 200uL pipette tip and media changed to conditioned or drugged media. 
Phase contrast images were taken to the left or right of the center of the cross 
wound at 10x at 0 hour and 16 hour time points. Scratch size in each image was 
quantified using the Scratch Assay Analyzer tool in the MiToBo extension in 
ImageJ 2.0 with sigma = 2 and entropy filter = 25 and verified by hand. The 
percent of wound healing was calculated by dividing the wound area at 16 hours 
by the wound area at 0 hours, subtracting the resulting value from 1, and 
multiplying by 100 (17).  
Microchannel migration assays: 
A polydimethylsiloxane (PDMS) microfluidic device was produced by 
standard photolithography and replica molding, comprised of an array of 
microchannels 200um long, 10um tall, with widths of 3um, 6um, 10um, 20um, or 
50um, as previously described (17). Prior to cell seeding, the PDMS device and 
glass coverslip were plasma cleaned, and the PDMS device was adhered to the 
glass surface. Collagen Type I (BD Biosciences) at 20 ug/mL in phosphate 
buffered saline (PBS) was absorbed for one hour at 37C, then aspirated and 
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washed with PBS before cell seeding. Cells were trypsinized, washed with HBSS 
and suspended at 50,000 cells in 50uL low growth factor media (DMEM with 2% 
C/D FBS, 1% Pen/Strep) in a well at one end of the device. The well at the 
opposite end was filled with full growth factor media with NGF.   Time-lapse 
microscopy images were taken at 10 minute intervals for 12 hours. Cell bodies 
were identified by hand in each frame with the x-y position of a cell defined by 
the central cell body, and values for cellular velocity, displacement and distance 
traveled were calculated with a custom MATLAB program (17). 
Immunohistochemistry: 
Confluent T75 flasks were trypsinized and centrifuged to form cell pellets. 
Cell pellets were fixed in formalin for 24 hours before paraffin embedding, 
sectioning and adherence to slides. Slides were steamed in EDTA solution and 
incubated with anti-TrkA rabbit monoclonal antibody (2505S; Cell Signaling). 
Poly-HRP anti-rabbit IgG antibody was applied and then visualized with 3,3’-
diaminobenzidine (Sigma). Slides were counterstained with hematoxylin (18). 
Xenograft assays: 
For each group, a minimum of five 8- to 10-week old female athymic nude 
mice (Harlan Laboratories, Indianapolis, IN) were provided with estrogen pellet 
supplementation prior to cell injection. For solid tumor formation studies, cell 
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solutions were prepared in a 20% sterile PBS, 80% growth factor-reduced 
Matrigel (BD Biosciences) containing 1 million cells/200uL and injected 
subcutaneously in either flank at 200uL. Tumor volumes were measured weekly 
and calculated by multiplying width, length and height for each individual 
tumor.  
For tail vein injection assays, cell suspensions were prepared in sterile PBS 
at .5 million cells/200uL and injected at 200uL into the tail vein of 8- to 10-week-
old female athymic nude mice. Mice were monitored for signs of disseminated 
tumor formation including palpable mass and discomfort, and euthanized as 
appropriate. Tissues and tumors were excised and fixed in 10% formalin before 
embedding in paraffin, sectioning, and staining with hematoxylin and eosin. 
Tissues were examined grossly, and 5 stained sections were examined for 
evidence of multicellular, proliferating disease per experimental group under a 
phase contrast microscope.  
All animal experiments were performed in accordance with institutional 
and The National Institutes of Health Guide for the Care and Use of Laboratory 






All statistical analyses were performed using GraphPad Prism 5 software 
(GraphPad Software). Unpaired Student's T tests, 1-way ANOVA, and 2-way 
ANOVA tests were used to compare experimental groups to the appropriate 
control. Significance levels are indicated by asterisks: P<= 0.05 (*), P<= 0.01 (**) 














Overexpression of TrkA protein in non-tumorigenic human breast epithelial 
cell lines 
With the goal of producing a breast cell model demonstrating the impact 
of TrkA overexpression, two non-tumorigenic human breast cell lines were 
transfected with a pIRESneo3 plasmid containing a human full length NTRK1 
cDNA, single cell isolated and confirmed to express the TrkA protein by western 
blot and immunohistochemistry of cell pellets (Figure 1, Figure 11). MCF10A is a 
spontaneously immortalized mammary cell line that grows best in media 
containing supraphysiologic (20ng/mL) epidermal growth factor (EGF), insulin, 
18 
 
and cholera toxin. hTERT-IMEC is a mammary cell line immortalized by human 
TERT protein expression that is similarly non-tumorigenic in 
immunocompromised mice and is grown in similar media factors. Neither 
parental cell line expresses the TrkA protein at significant levels, as confirmed by 
western blot and immunohistochemistry of cell pellets. For each of these two 
parental cell lines, four independent TrkA-overexpressing clones were isolated 
(referred to as MN1-4 and HIN2-5) as well as one empty vector control 
expressing the pIRESneo3 plasmid containing no cDNA (MEV and HIpI) (Figure 
1). TrkA-overexpressing and empty vector clones were continuously maintained 
under Geneticin selection. The MCF10A cell line arrests under growth factor 
restricted conditions in media lacking EGF and replacing horse serum with 
charcoal/dextran stripped (C/D) fetal bovine serum (FBS). The hTERT-IMEC cell 
line takes several days to arrest under these conditions, and thus these cells were 
prepared for assays by plating in these conditions for 48 hours before plating for 
assays. As an additional positive control, MCF10A cells were transfected with a 
plasmid containing CD74-NTRK1 translocation cDNA, and three clones isolated 




Non-tumorigenic breast cells show growth factor-independent growth when 
overexpressing TrkA 
Parental MCF10A and hTERT-IMEC require supraphysiologic EGF as well 
as insulin in order to grow well. Growth factor independence represents a 
hallmark of cancer, and EGF independence is a phenotype that has been 
previously produced in MCF10A-derived cell lines when transformed by 
oncogenic mutations (19). In order to determine whether this was a characteristic 
imparted by TrkA overexpression, we performed several cell growth assays 
comparing TrkA overexpressing and fusion expressing cell lines to the parental 
cell lines under growth-factor limited (physiologic EGF, 0.2 ng/uL) and arrest (no 
EGF, no insulin) conditions.  
In cell growth assays by crystal violet staining and by cell counting, the 
TrkA-overexpressing MCF10A and hTERT-IMEC and CD74-NTRK1-expressing 
MCF10A show proliferation under EGF-free growth limiting conditions as 
compared to arrest media in the parental and empty vector controls (Figures 4-
10, Figure 27). This effect is replicated in the MCF10A cell lines under media 
conditions with physiologic EGF (0.2ng/mL), where the TrkA overexpressors 
outgrow the slow proliferation of the parental and empty vector controls. In 
repeating the growth assays in media lacking both EGF and insulin, here we 
demonstrated that TrkA overexpression results in both EGF independence and 
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insulin independence (Figure 32). In each of these conditions, the addition of the 
TrkA ligand neuronal growth factor (NGF) increases the growth advantage 
observed. Treatment with larotrectinib diminishes or reverses this growth factor 
independence phenotype. TrkA overexpression in human epithelial breast cells 
produces EGF and insulin-independent growth that can be effectively targeted 
with the inhibitor larotrectinib. 
TrkA-overexpressing clones show amplified signaling in growth and survival 
pathways  
Downstream of TrkA activation and phosphorylation are the pro-growth 
and pro-survival MAPK (via ERK-RSK1) and AKT (via AKT-P70S6K) pathways. 
Assaying for phosphorylated forms of these pathway proteins by western blot 
gives a clear picture of increased activation in the TrkA-overexpressing and 
translocation expressing clones (Figures 12-16, Figure 29). This is particularly 
amplified in the presence of NGF for the TrkA overexpressors, and diminished 
or abolished with the addition of larotrectinib even in the presence of NGF. 
Specifically, levels of phospho-TrkA, phospho-AKT, phospho-P70S6K, phospho-
ERK, and phospho-P90RSK1 are elevated by TrkA-NGF in the MCF10A-derived 
cell lines, whereas the phospho-AKT phenotype was not observed in the hTERT-
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IMEC-derived cell lines and the P90RSK1 expression was too low under growth 
factor reduced conditions to detect.  
Increased irregularity and amplified anchorage-independent growth in three-
dimensional culture  
When cultured at low density in Matrigel under low growth factor 
conditions, the parental and empty vector expressing MCF10A and hTERT-IMEC 
form relatively small, regular spherical acini. By comparison, the TrkA-
overexpressing and translocation expressing clones form larger and more 
irregular colonies that are frequently connected to each other or spiculated 
(Figures 17, 18, Figure 30). This effect is particularly pronounced in TrkA 
overexpressing clones in the presence of NGF, which resulted in many 
interconnected colonies for the MCF10A and formations like nodes connected by 
relatively long bridges for the hTERT-IMEC. These effects were blocked by the 
addition of larotrectinib, which restored even the clones in the presence of NGF 
to small, regular spheroids.  
When cultured in soft agar, once again parental and empty vector 
expressing cells formed a few, regular spheres in each field of view. TrkA 
overexpressing and translocation lines formed many more and larger colonies, 
demonstrating not only increased growth rates but also increased anoikis 
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resistance and anchorage-independent growth (Figures 19, 20). These effects 
were increased in the TrkA-overexpressing cells in the presence of NGF and 
reduced or ablated in the presence of the inhibitor larotrectinib in overexpression 
and translocation clones. 
Increased wound healing and migration 
As one of the first stages of metastasis requires cells to migrate from the 
central tumor body to the circulation, migratory capacity may be indicative of a 
possible metastatic phenotype. Under growth-factor limited conditions, the 
parental MCF10A and hTERT-IMEC show reduced capacity for scratch-wound 
healing. In order to determine whether the migratory capacity of the 
overexpression clones was altered, we performed scratch wound healing and 
microchannel migration assays. When plated to a confluent monolayer and 
scratched to mimic a wound, followed by imaging over time, an increased 
migration and wound healing phenotype was observed in the TrkA-
overexpressing and translocation cell lines (Figures 21, 22, Figure 31). An 
interesting change in morphology while migrating was observed in the MCF10A-
derived TrkA overexpression clones in the presence of NGF. Typically, the 
advancing front of cells as the wound closes migrate in a fairly regular fashion, 
resulting in a slightly ragged but relatively even edge. In the MCF10A TrkA-
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overexpressing lines with NGF, the advancing lines were wavy and uneven, 
suggesting perhaps a difference in migration not otherwise observed (Figure 23).  
Because an increased growth phenotype had already been observed in 
these cell lines, it was important to perform migration assays that were 
independent of growth, which the scratch assay is unable to fully separate. For 
this purpose, trypsinized MN or MEV cells were suspended in growth factor-free 
media separated from a well containing normal media containing NGF by 
microchannels of various widths. Time lapse imaging allowed the tracking of 
individual cells as they migrate up the chemotactic gradient. This produced 
measures of speed, persistence and velocity. Speed is here defined as the amount 
of movement an individual cell shows, independent of direction. Persistence 
quantifies the extent to which a cell continues to move across the channel, with a 
perfectly straight path from low growth factor media to high growth factor 
media having a value of 1. The product of these two quantities is the velocity, 
which reflects the migratory capacity of the cell.  
In these assays, the speed of the TrkA overexpressors was observed to be 
double that of the empty vector control, reflecting a more motile cell (Figure 24). 
The persistence showed no significant difference (Figure 25). Velocity, the 
measure of migration, was significantly higher in the TrkA overexpressors as 
compared to the empty vector control (Figure 26). These assays were performed 
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in channels of varying widths from 3 uM to 20 uM. It was additionally observed 
that the TrkA overexpressors were more likely to enter the two smallest sets of 
channels, and so few cells entered these smallest channels for the empty vector 
control that these were impossible to accurately measure. The addition of the 
inhibitor larotrectinib had the effect of decreasing the speed and velocity 
measures, as well as causing the TrkA overexpressors to enter the smallest 
channels less frequently.  
TrkA overexpression alters gene expression 
Gene expression under growth arrest conditions in the presence of NGF 
were compared by microarray for one TrkA-overexpressing clone and the empty 
vector control of the MCF10A and hTERT-IMEC cell lines. Multiple genes were 
identified as being differentially expressed in both comparisons, listed in Tables 
4 and 5. Of the genes listed, several have been identified in the literature as being 
involved in breast cancer tumorigenesis, metastasis, or progression.  
HIST1H2BM encodes a histone protein increased in breast cancer progression in 
the MCF10AT model (20). FEN1, flap endonuclease 1, is elevated in DNA 
damage, interacts with APC to promote breast cancer development, (21) and is 
associated with poor prognosis and highly aggressive tumor types (22). 
HSD17B2, hydroxysteroid 17b-dehydrogenase type 2, is modulated by estrogen 
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exposure (23),  catalyzes conversion between estrogen forms, and is upregulated 
in ER-negative breast cancer (24).  IL-1A, interleukin 1A, is involved in a pro-
inflammatory feed-forward loop that promotes breast cancer tumorigenesis and 
chemotherapy resistance (25). FBXO45, F-box protein 45, is an E3 ubiquitin ligase 
that is involved in estrogen receptor degradation (26) and altering 
chemosensitivity (27). SFN, stratifin, is important to cellular movement and 
correlated with poor progression and aggressive breast cancer subtypes (28). 
ERCC6L, excision repair cross-complementation group 6 like, is a DNA helicase 
that promotes cell proliferation and survival in breast cancer (29). EFNB2, ephrin 
B2, is prognostic for poor breast cancer survival when cytoplasmic rather than 
membrane-bound (30), is a target of TGFb in pro-invasive and migratory 
processes (31), and modulates expression of metalloproteases MMP9 and MMP2 
in these invasive processes (32). PLAGL2, pleomorphic adenoma gene like-2, is a 
zinc finger translational factor that promotes migration by interacting with the 
actin cytoskeleton (33). Of the downregulated genes, TSHZ2 is a zinc finger 
homeobox protein that releases tumorigenesis-promoting GLI1 when 
downregulated in breast cancer (34) and TSC22D3, glucocorticoid leucine zipper, 
is an apoptosis-regulating transcription factor downregulated by estrogen in 




TrkA overexpression increases growth in a tumorigenic breast cell line in vivo 
 
Initial assays in NOD-SCID mice indicated that the overexpression of 
TrkA does not confer tumorigenicity on the MCF10A cell line. Therefore, a TrkA-
overexpression model was developed in the tumorigenic MCF7 cell line by the 
protocol described above in order to produce an in vivo model. Briefly, multiple 
isogenic TrkA-overexpressing clones as well as an empty vector control were 
produced by single-cell isolation of transfected MCF7 cells. Western blot was 
utilized to confirm overexpression of the TrkA protein as compared to the low 
but detectable level seen in the parental MCF7.  In mice, TrkA overexpression 
conferred higher proliferation but did not confer estrogen independence (Figure 
33). TrkA expression in the tumors was confirmed by immunohistochemistry.  
No gross metastases were observed. In the tumorigenic MCF7 cell line, TrkA 
overexpression increases proliferation in vivo but does not alter estrogen 
dependence or invasiveness.  
TrkA overexpression confers the capacity for disseminated disease formation 
The MCF7 cell lines were next interrogated by tail vein injection to 
determine the capacity for disseminated disease formation, an indicator of 
metastatic capacity. Whereas the parental MCF7 cell line does not form tumors 
when injected in the tail vain, the TrkA-overexpressing MCF7 cell lines formed 
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microscopic and macroscopic tumors in lung as well as salivary gland and other 




Cell Line Description 
MCF10A Parental MCF10A cell line 
MEV MCF10A expressing pIRESneo3 vector 
MN1 MCF10A expressing NTRK1-pIRESneo3 vector 
MN2 MCF10A expressing NTRK1-pIRESneo3 vector 
MN3 MCF10A expressing NTRK1-pIRESneo3 vector 
MN4 MCF10A expressing NTRK1-pIRESneo3 vector 
hTERT-IMEC Parental hTERT-IMEC cell line 
HIpI hTERT-IMEC expressing pIRESneo3 vector  
HIN2 hTERT-IMEC expressing NTRK1-pIRESneo3 vector 
HIN3 hTERT-IMEC expressing NTRK1-pIRESneo3 vector 
HIN4 hTERT-IMEC expressing NTRK1-pIRESneo3 vector 
HIN5 hTERT-IMEC expressing NTRK1-pIRESneo3 vector 
CDN2 MCF10A expressing CD74-NTRK1 translocation vector 
CDN3 MCF10A expressing CD74-NTRK1 translocation vector 
CDN4 MCF10A expressing CD74-NTRK1 translocation vector 
MCF7 Parental MCF7 cell line 
MCF7 EV Parental MCF7 cell line expressing pIRESneo3 vector 
MCF7 TrkA MCF7 expressing NTRK1-pIRESneo3 vector 
 




Primer Name Sequence 
R ntrk1 center GCACTCAGCAAGGAAGACCT 
F ntrk1 center GGCAGAGGTCTCTGTTCAGG 
R ntrk1 RC213091 TTGCTGCCAGATCCTCTTCT 
F ntrk1 RC213091 GATCCGGTACCGAGGAGAT 






NTRK1cDNA R2 TTGTCCATGAAGGCAGCCAT 
NTRK1 cDNA F2 TGGTCTCATTGAGCACGGAG 
NTRK1 cDNA R1 AATGGCTCCGTGCTCAATGA 
NTRK1 cDNA F1 AGGGTTGTCCATGAAGGCAG 
pIRES-MCS-ntrk1 R2 AACGCCACAGCATCAAGGAT 
pIRES-MCS-ntrk1 F2 GTACTCACCCCAACAGCTGG 
pIRES-MCS-ntrk1 R1 CAGCATCAAGGATGTGCACG 
pIRES-MCS-ntrk1 F1 GGAGTACTCACCCCAACAGC 
 

















METABRIC 2051 436 21.26% - - - 
BCCRC 
Xenograft 
29 4 13.79% - - - 
The MBC 
Project 
103 13 12.62% - - - 
TCGA 2015 505 55 10.89% 5 1 20% 
TCGA 963 102 10.59% 60 13 21.67% 
Sickkids 
2016 
213 17 7.98% - - - 
TCGA Pub 482 22 4.98% 123 11 8.94% 
 




 Fold Change in MCF10A Fold Change in hTERT-IMEC 
HIST1H2BM 2.00E+05 4.09E+02 
FEN1 1.31E+03 2.37E+01 
SPINK6 8.70E+02 8.61E+00 
HIST1H3I  7.29E+02 4.89E+01 
GSG2 3.76E+02 2.76E+01 
HIST1H2AG 1.73E+02 1.85E+01 
CHAC2 1.56E+02 7.87E+00 
HYLS1  1.16E+02 5.36E+00 
HSD17B2 7.55E+01 7.35E+01 
PIGW 6.42E+01 1.34E+01 
HIST1H2BL 4.62E+01 1.48E+01 
MT1G 3.55E+01 3.76E+00 
IL1A 2.60E+01 3.05E+01 
EEF1E1 2.19E+01 5.58E+00 
PGP 1.81E+01 3.67E+00 
HIST2H2AB 1.66E+01 2.82E+01 
LLPH 1.52E+01 3.58E+00 
TRIM59 1.21E+01 3.78E+00 
FBXO45 1.17E+01 3.63E+00 
HIST1H4L 1.12E+01 3.39E+01 
MT1M 1.08E+01 3.90E+00 
CEBPG 9.73E+00 3.37E+00 
HAUS2 8.57E+00 7.09E+00 
TMEM97 8.02E+00 1.91E+01 
HIST1H2BO 7.86E+00 1.61E+01 
C5orf30 7.79E+00 4.86E+01 
SFN 7.47E+00 1.34E+01 
HIST1H2BH 7.44E+00 1.77E+01 
IFIT3 7.42E+00 1.33E+04 
ERCC6L 7.24E+00 2.21E+01 
EFNB2 6.42E+00 6.27E+00 
C10orf12  5.58E+00 2.66E+01 
TIFA 4.42E+00 6.47E+00 
IER3 4.36E+00 3.88E+01 
HIST1H2BE 4.20E+00 1.39E+01 
CLIC1 4.13E+00 3.90E+00 
HIST1H4C 4.02E+00 2.27E+01 
MID1IP1 3.95E+00 3.24E+00 
PLAGL2 3.21E+00 3.95E+00 
 
Table 4:  Genes upregulated in TrkA- overexpressors by microarray.  
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 Fold Change in MCF10A Fold Change in hTERT-IMEC 
PCDHB5 2.94E-01 1.18E-01 
CBLN3 2.51E-01 1.50E-01 
TACSTD2 2.50E-01 8.87E-02 
IRX5 2.25E-01 2.25E-01 
PCDHB3 2.10E-01 2.40E-01 
DIRC1 1.86E-01 1.31E-01 
FAM229B 1.81E-01 1.35E-01 
RWDD2A 1.70E-01 2.64E-01 
TMEM127 1.66E-01 2.57E-01 
MB21D2 1.62E-01 1.74E-01 
PCDHB16 1.52E-01 1.84E-03 
GJA5 1.43E-01 1.50E-01 
TCEAL3 1.39E-01 2.49E-01 
GPR1 1.22E-01 9.37E-03 
PCDHB10 7.48E-02 9.70E-02 
TSHZ2 6.99E-02 2.85E-01 
TSC22D3 4.25E-03 4.21E-02 
CITED2 7.07E-05 2.98E-01 
 







Figure 1: Experimental design. NTRK1 cDNA was isolated by PCR from 
RC213091 vector and ligated to pIRESneo3 vector, transfected using Fugene 
reagents, and multiple independent clones isolated in MCF10A and hTERT-






Figure 2: TrkA alterations across breast cancer studies as found in TCGA data via 






Figure 3: Kaplan-Meier survival curves in breast invasive carcinoma, TCGA data, 
Cell 2015 dataset for breast cancers with GISTIC putative copy number 
alteration. In this data, alteration in TrkA confers a 40 month survival 




Figure 4: Parental MCF10A, empty vector control MEV and TrkA-overexpressing 
clones MN1-4 plated at 30,000 cells/well in 24-well plates, changed to the 
specified media at 24 hours, and stained with crystal violet at 5 days. Images 
taken from larger plates in smaller groups to avoid parallax effect. MCF10A 
arrest media, epidermal growth factor (EGF) added at 0.2 ng/mL, neuronal 







Figure 5: Parental hTERT-IMEC, empty vector control hIpI and TrkA-
overexpressing clones HIN2-5 plated at 30,000 cells/well in 24-well plates, 
changed to the specified media at 24 hours, and stained with crystal violet at 5 
days. hTERT-IMEC arrest media, neuronal growth factor (NGF) added at 12.5 







































Figure 6: Parental MCF10A, empty vector control MEV and TrkA-overexpressing 
clones MN1-4 plated at 30,000 cells/well in triplicate in 24-well plates, changed to 
the specified media at 24 hours, and counted with a Beckman-Coulter cell 
counter at 2, 4, and 6 days. Mean ± SEM shown, ** P ≤ 0.001, NS = not significant 
by ANOVA at 6 day time point. (A) Proliferation averages, arrest media alone (B) 




























Figure 7: Parental MCF10A, empty vector control MEV and TrkA overexpressing 
clones MN1-4 plated at 30,000 cells/well in triplicate in 24-well plates, changed to 
the specified media at 24 hours, and counted with a Beckman-Coulter cell 
counter at 2, 4, and 6 days. Mean ± SEM shown, ** P ≤ 0.001, NS = not significant 
by ANOVA at 6 day timepoint. (A) Proliferation averages, arrest media with 
physiologic levels of epidermal growth factor (EGF) at 0.2 ng/mL (B) 
Proliferation averages, arrest media with physiologic levels of epidermal growth 




























Figure 8: Parental MCF10A, empty vector control MEV and TrkA overexpressing 
clones MN1-4 plated at 30,000 cells/well in triplicate in 24-well plates, changed to 
the specified media at 24 hours, and counted with a Beckman-Coulter cell 
counter at 2, 4, and 6 days. Mean ± SEM shown, ** P ≤ 0.001, NS = not significant 
by ANOVA at 6 day time point. (A) Proliferation averages, arrest media with 
physiologic levels of epidermal growth factor (EGF) at 0.2 ng/mL and 
larotrectinib, 1.5uM (B) Proliferation averages, arrest media with physiologic 
levels of epidermal growth factor (EGF) at 0.2 ng/mL, neuronal growth factor 



























Figure 9: Parental hTERT-IMEC, empty vector control hIpI and TrkA 
overexpressing clones HIN2-5 plated at 30,000 cells/well in triplicate in 24-well 
plates, changed to the specified media at 24 hours, and counted with a Beckman-
Coulter cell counter at 2, 4, and 6 days. Mean ± SEM shown, ** P ≤ 0.001, NS = not 
significant by ANOVA at 6 day time point. (A) Proliferation averages, arrest 
media (B) Proliferation averages, arrest media with neuronal growth factor 




























Figure 10: Parental hTERT-IMEC, empty vector control hIpI and TrkA 
overexpressing clones HIN2-5 plated at 30,000 cells/well in triplicate in 24-well 
plates, changed to the specified media at 24 hours, and counted with a Beckman-
Coulter cell counter at 2, 4, and 6 days. Mean ± SEM shown, **P ≤ 0.001, NS = not 
significant by ANOVA at 6 day time point. (A) Proliferation averages, arrest 
media with larotrectinib, 1.5uM (B) Proliferation averages, arrest media with 








Figure 11: TrkA is expressed externally in overexpression cell lines (MN1-4, 
HIN2-5) and not in parental (MCF10A, hTERT-IMEC) or empty vector controls 
(MEV, hIpI). Cell pellets were fixed, sectioned, and stained with anti-TrkA 






Figure 12: Western blots show activation in growth and survival pathways in 
TrkA overexpression lines, which is amplified with the addition of NGF and can 
be blocked with the inhibitor larotrectinib. Protein lysates for parental MCF10A, 
empty vector control MEV and TrkA overexpressing clones MN1-4 were 
collected after 24 hour exposure to arrest media conditions with and without 






Figure 13: Protein lysates for parental MCF10A, empty vector control MEV and 
TrkA overexpressing clones MN1-4 were collected after 24 hour exposure to 
arrest media conditions supplemented with EGF at 0.2ng/mL with and without 
NGF at 100ng/mL and subjected to western blot analysis with the indicated 





Figure 14: Protein lysates for parental MCF10A, empty vector control MEV and 
TrkA overexpressing clones MN1-4 were collected after 24 hour exposure to 
arrest media conditions supplemented with EGF at 0.2ng/mL and larotrectinib at 
1.5uM, with and without NGF at 100ng/mL and subjected to western blot 





Figure 15: Protein lysates for parental hTERT-IMEC, empty vector control hIpI 
and TrkA overexpressing clones HIN2-5 were collected after 24 hour exposure to 
arrest media conditions with and without NGF at 12.5ng/uL and subjected to 






Figure 16: Protein lysates for parental hTERT-IMEC, empty vector control hIpI 
and TrkA overexpressing clones HIN2-5 were collected after 24 hour exposure to 
arrest media conditions with larotrectinib at 1.5uM, with and without NGF at 





Figure 17: TrkA overexpression changes morphology and increases anchorage 
independent growth in three-dimensional culture. Parental MCF10A, empty 
vector control MEV and TrkA overexpressing clones MN1-4 were cultured in 
low growth factor conditions at low density in Matrigel under specified 
conditions. TrkA overexpressing clones showed larger, more irregular and 
spiculated colonies, exacerbated by neuronal growth factor (NGF) and reversed 





Figure 18: Parental hTERT-IMEC, empty vector control hIpI and TrkA 
overexpressing clones HIN2-5 were cultured in low growth factor conditions at 
low density in Matrigel under conditions specified. TrkA overexpressing clones 
showed larger, more irregular and spiculated colonies, exacerbated by neuronal 






Figure 19: Parental MCF10A, empty vector MEV and TrkA overexpressing 
clones MN1-4 were cultured in low growth factor conditions at low density in 
0.8% agar for two weeks, stained with crystal violet and imaged in multiple 
fields of view for colony quantification. TrkA overexpressing clones formed 
more colonies per field of view (FOV), increased by NGF and reduced by 
larotrectinib. Mean ± SEM shown, ** P ≤ 0.001, NS = not significant by ANOVA.  
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Figure 20: Parental hTERT-IMEC, empty vector hIpI and TrkA overexpressing 
clones HN2-5 were cultured in low growth factor conditions at low density in 
0.8% agar for two weeks, stained with crystal violet and imaged in multiple 
fields of view for colony quantification. TrkA overexpressing clones formed 
more colonies per field of view (FOV), increased by NGF and reduced by 







Figure 21: TrkA overexpression confers a migration advantage and changes 
wound healing morphology in MCF10A. Parental MCF10A, empty vector control 
MEV and TrkA overexpressing clones MN1-4 were plated to a confluent 
monolayer, scratched, and imaged at 0 and 16 hour time points; percent healing 
calculated from scratch dimensions quantified with ImageJ MiToBo software. 
TrkA overexpression confers higher wound healing especially with TrkA ligand 
































































Figure 22: Parental hTERT-IMEC, empty vector control hIpI and TrkA 
overexpressing clones HIN2-5 plated to a confluent monolayer, scratched, and 
imaged at 0 and 16 hour time points; percent healing calculated from scratch 
dimensions quantified with ImageJ MiToBo software. TrkA overexpression 
confers higher wound healing especially with TrkA ligand neuronal growth 







Figure 23: Representative images of MCF10A scratch assays. TrkA 
overexpressing clones MN1-4 supplemented with ligand NGF show uneven, 




























Figure 24: Microchannel migration assays were performed tracking individual 
cells across variously sized channels along a growth factor gradient. (A) TrkA 
overexpressing clone showed higher instantaneous speed (B) Larotrectinib 



























Figure 25: Microchannel migration assays were performed tracking individual 
cells across variously sized channels along a growth factor gradient. (A) TrkA 
overexpressing clone showed no significant difference in persistence (net cell 





























Figure 26: Microchannel migration assays were performed tracking individual 
cells across variously sized channels along a growth factor gradient. (A) TrkA 
overexpressing clone showed higher cellular velocity, calculated as the product 






























Figure 27: Modeling a CD74-NTRK1 fusion expression in an MCF10A 
recapitulates growth advantage and larotrectinib sensitivity under growth-
limiting media conditions as seen in TrkA overexpression model. CD74-NTRK1 
expressing isogenic clones (CDN2-4) show proliferative advantage over parental 





Figure 28: Confirmation of TrkA expression by immunohistochemistry; antibody 
binds region in fusion sequence. Cells were collected, pelleted, and pellets 
preserved in formalin before paraffin embedding, sectioning, and 






Figure 29: Modeling a CD74-NTRK1 fusion expression in MCF10A recapitulates 
phosphorylation signaling amplification and larotrectinib sensitivity under 
growth-limiting media conditions as seen in TrkA overexpression model.  
Protein lysates were prepared from CD74-NTRK1 fusion cell lines and parental 
MCF10A after 24 hours in arrest conditions with and without larotrectinib, 
subjected to western blot and probed for the specified antibodies. 
Phosphorylation of AKT, ERK, and P90RSK1 is increased in CDN clones, 





















Figure 30: Modeling a CD74-NTRK1 fusion expression in an MCF10A 
recapitulates morphology and anchorage independence in three-dimensional 
culture and larotrectinib sensitivity under growth-limiting media conditions as 
seen in TrkA overexpression model. Three-dimensional culture in Matrigel (A) 
and soft agar (B) gives slightly larger colonies, with larotrectinib reducing to 







Figure 31: Modeling a CD74-NTRK1 fusion expression in an MCF10A 
recapitulates increased wound healing, and larotrectinib sensitivity under 
growth-limiting media conditions as seen in TrkA overexpression model. 
Confluent monolayers were scratched and imaged at 0 and 16 hours, and percent 


















Figure 32: TrkA overexpression confers insulin independence. MCF10A parental 
cell line, MEV empty vector control, MN1-4 TrkA overexpression clones were 
plated at 30,000 cells/well and changed to insulin-free assay media with or 
without NGF at 100ng/mL after 24 hours. (A, B) Average proliferation as 
performed by cell counts on a Beckman Coulter cell counter at day 2, 4, 6 with 


























Figure 33: TrkA overexpressing isogenic clones of the tumorigenic breast line 
MCF7 were generated for in vivo work. NOD-SCID mice were injected 
subcutaneously with empty vector control or TrkA-overexpressing MCF7 cells. 
(A) TrkA overexpression gives a proliferative advantage but does not confer 
estrogen independence in MCF7. (B) TrkA expression in tumors confirmed by 















Figure 34: Representative images of lungs of mice after tail vein injection. MCF7 
empty vector control does not form disseminated disease after tail vein injection. 
(A) Lung section, empty vector expressing MCF7, 4x. (B) Lung section,  empty 

















Figure 35: Representative images of lungs of mice after tail vein injection. TrkA 
overexpression in MCF7 confers the ability to form disseminated disease after 
tail vein injection. Small tumors adjacent to blood vessels as well as 
macroscopically visible tumors were formed in lung. (A) Lung section, TrkA-














As we delve deeper into mutational mapping of tumor formation and 
tumor progression, it is evident that personalizing medicine by targetable 
mutations will be more successful than by tissue of origin. Leveraging inhibitors 
designed for cancers of other origins to cross boundaries offers potential for 
intersecting extant therapies with new tumor types. Releasing the highly 
aggressive triple negative breast cancers from the limitations of cytotoxic 
chemotherapy, radiation and surgery is a key endeavor. The dramatic changes 
induced in this preclinical breast model with the overexpression seen in patients 
as well as its reversibility with larotrectinib give support to this intersecting 
approach in the model constructed for our studies. Here, our results 
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demonstrated the characteristics of TrkA amplification as a driver mutation in 
breast cancer across independent clones and multiple cell lines, and also suggest 
larotrectinib as a specific therapy in these models. 
In our studies, we demonstrated that TrkA overexpression was 
transformative and targetable, causing amplification of cancer-associated 
phenotypes that was reversed under treatment with larotrectinib.  TrkA 
overexpressors showed not only advantages in proliferation in both monolayer 
and three dimensional culture as well as signaling activation, but migratory 
alterations that could promote and assist metastasis. A putative autocrine TrkA-
NGF loop has been established in the MCF7 cell line. Publications vary on the 
exact levels of neuronal growth factor present in breast and other tissues but 
agree on the presence of the ligand endogenously. Tumors expressing TrkA may 
have growth and migratory advantages, and the chemotactic migratory NGF 
pathway could promote metastasis and even contribute to the tropism of breast 
cancers to the NGF-high brain tissue. Notably, the enhanced tendency of the 
TrkA overexpressing cells to enter small channels in our migration assays, and 
not just the rate of migration, was reduced in kind by larotrectinib.  
We recognize the limitations of our studies in modeling amplification of 
TrkA in breast cancer in that artificial transgene overexpression does not fully 
represent the range of amplification levels seen in patients, as well as the 
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potential positional effects of plasmid integration location. The latter we 
endeavored to minimize by studying multiple independent clones against both 
parental and empty vector controls in order to differentiate between clonal 
effects and the impact of the overexpression on phenotypes seen. The 
effectiveness of larotrectinib for breast cancer may indeed vary with the degree 
of amplification, which could perhaps be mitigated by setting a minimum 
threshold for treatment, similar to Herceptin in HER2 positive breast cancers. 
Additionally, the doses of larotrectinib required in order to inhibit these 
phenotypic changes were higher than anticipated. However, the doses required 
for the inhibition of the TrkA overexpression clones were matched to those 
required for our in vitro studies of the translocation clones, and given the 
significant responses to larotrectinib in translocations in ongoing clinical studies, 
we anticipate that this observation does not limit the potential clinical utility of 
larotrectinib for amplifications. Previous studies have also observed that high 
levels of various chemotherapeutic drugs are required to see effects in the non-
tumorigenic MCF10A cell line (15).   
Amplification of TrkA is broadly represented across numerous tumor 
types and multiple studies, suggesting a future for this inhibitor in a broad range 
of cancers showing this feature. Our study highlights migratory and metastatic 
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phenotypes as a key product of TrkA overexpression and validates the efficacy of 
larotrectinib in a TrkA overexpression model in breast cancer.  
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